# Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy

> **NCT00858806** · PHASE2 · COMPLETED · sponsor: **Università degli Studi di Brescia** · enrollment: 78 (actual)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT00858806
- **Lead sponsor:** Università degli Studi di Brescia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2010-12
- **Final completion:** 2014-12
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2014-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00858806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00858806, "Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00858806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*